An executive summary evaluating the rapid rise of antibody-drug conjugates (ADCs) in China, global licensing trends, and international clinical trial regulatory hurdles.
Novotech: ADCs – Opportunities and Challenges for Chinese Biotech Companies
Home Clinical & Biopharma Novotech: ADCs – Opportunities and Challenges for Chinese Biotech Companies
